ARBN top pick on strong pace of approvals: Citigroup

By: |
Updated: Aug 29, 2015 6:35 AM

After a light FY15, ARBN has received 15 approvals in FY16 YTD. This is a mix of plain-vanilla and limited competition products.

Entecavir is Aurobindo Pharma (ARBN’s) 15th approval in FY16. If this pace continues, revenues could ramp up meaningfully over the next few years. We remain comfortable with our above-consensus estimates and maintain ARBN as our top pick.

After a light FY15, ARBN has received 15 approvals in FY16 YTD. This is a mix of plain-vanilla and limited competition products. While some are small, they add to ARBN’s positioning as a one-stop shop across categories.

This works in its favour in the current “channel consolidation” environment, as customers rationalise vendor lists.

ARBN has been a key beneficiary over the last two years and we expect this to continue.

While new approvals help everyone, we believe ARBN faces the least risk to its base biz, as it has a large number of small to medium-sized products and no pockets of supernormal pricing. The pipeline is strong (180+ pending ANDAs) and improving. Also, 85%+ of pending ANDAs are from sites that were successfully inspected recently.

ARBN makes up 26% of the total ANDA approval count for Indian companies in FY16.

We expect gEntecavir (US$285m market) to be a potentially chunky & sustainable product for Aurobindo.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Covid pandemic hits IPOs in India; stock exchanges see just 4 IPOs in June quarter, says report
2FPIs pull out Rs 3,741 crore in three trading sessions in July
3MF investment in equity markets rises to Rs 39,500-cr in H1 2020 on attractive valuations